FDA panel backs Merck's at-home COVID pill

Tuesday, 30. November 2021 23:55

A United States Food and Drug Administration (FDA) advisory committee determined that benefits outweigh the risks and endorsed Merck and Ridgeback Biotherapeutics' COVID-19 treatment pill.

If officially authorized, the antiviral medication, molnupiravir, would be the first oral at-home treatment for adults with mild to moderate coronavirus symptoms.

The drug still needs final FDA and Centers for Disease Control and Prevention (CDC) approval before it can be distributed across the country.

Related Links: Merck KGaAMerck & Co. Inc.
Baha Breaking News (BBN) / NL